| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Over the last 12 months, insiders at ADC Therapeutics S.A. have bought $0 and sold $0 worth of ADC Therapeutics S.A. stock.
On average, over the past 5 years, insiders at ADC Therapeutics S.A. have bought $2.86M and sold $278,289 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 200,000 shares for transaction amount of $609,000 was made by Redmile Group, LLC (10 percent owner) on 2024‑12‑11.
| 2024-12-11 | Redmile Group, LLC | 10 percent owner | 200,000 0.2806% | $3.04 | $609,000 | +23.65% | ||
| 2024-12-04 | Sale | Redmile Group, LLC | 10 percent owner | 25,352 0.0263% | $2.07 | $52,479 | +30.68% | |
| 2024-07-01 | Redmile Group, LLC | 10 percent owner | 800,000 0.9607% | $2.81 | $2.25M | -34.10% | ||
| 2024-06-17 | Sale | Pfisterer Thomas | director | 1,437 0.0018% | $2.89 | $4,153 | -14.01% | |
| 2024-06-17 | Sale | Hug Peter | director | 1,193 0.0015% | $2.89 | $3,448 | -14.01% | |
| 2024-06-17 | Sale | Monges Viviane | director | 1,437 0.0018% | $2.89 | $4,153 | -14.01% | |
| 2024-06-17 | Sale | Sandor Victor | director | 6,995 0.0086% | $2.89 | $20,216 | -14.01% | |
| 2024-06-17 | Sale | Squarer Ron | director | 6,995 0.0086% | $2.89 | $20,216 | -14.01% | |
| 2024-06-17 | Sale | BIZZARI JEAN-PIERRE | director | 6,995 0.0086% | $2.89 | $20,216 | -14.01% | |
| 2024-06-17 | Sale | Azelby Robert | director | 6,995 0.0086% | $2.89 | $20,216 | -14.01% | |
| 2024-05-07 | Sale | MALLIK AMEET | Chief Executive Officer | 29,731 0.0569% | $4.48 | $133,195 | -43.37% | |
| 2009-03-06 | FORET MICKEY P | director | 10,000 0.0118% | $2.75 | $27,500 | |||
| 2007-06-20 | Sale | SWITZ ROBERT E | PRES & CEO | 8,000 0.065% | $19.02 | $152,160 | ||
| 2006-06-20 | Rehfeld John E | director | 1,000 0.0069% | $16.14 | $16,135 | |||
| 2006-06-07 | FORET MICKEY P | director | 10,000 0.0746% | $17.46 | $174,600 | |||
| 2006-06-07 | MARTIN LOIS M | director | 1,000 0.0075% | $17.46 | $17,460 | |||
| 2006-06-05 | BLANCHARD JOHN A III | director | 15,000 0.1136% | $17.72 | $265,856 | |||
| 2004-01-16 | Sale | JOHNSON B KRISTINE | director | 16,000 0.0251% | $3.67 | $58,720 |
| Redmile Group, LLC | 10 percent owner | 15666731 12.647% | $65.49M | 2 | 1 | <0.0001% |
| MALLIK AMEET | Chief Executive Officer | 1167348 0.9423% | $4.88M | 0 | 1 | |
| Pfisterer Thomas | director | 213900 0.1727% | $894,102.00 | 0 | 1 | |
| Hug Peter | director | 182644 0.1474% | $763,451.92 | 0 | 1 | |
| SWITZ ROBERT E | PRES & CEO | 129297 0.1044% | $540,461.46 | 0 | 1 | |
| Monges Viviane | director | 106627 0.0861% | $445,700.86 | 0 | 1 | |
| Sandor Victor | director | 80886 0.0653% | $338,103.48 | 0 | 1 | |
| Squarer Ron | director | 80663 0.0651% | $337,171.34 | 0 | 1 | |
| BIZZARI JEAN-PIERRE | director | 79502 0.0642% | $332,318.36 | 0 | 1 | |
| Azelby Robert | director | 53005 0.0428% | $221,560.90 | 0 | 1 | |
| BLANCHARD JOHN A III | director | 39226 0.0317% | $163,964.68 | 1 | 0 | |
| FORET MICKEY P | director | 20000 0.0161% | $83,600.00 | 2 | 0 | |
| JOHNSON B KRISTINE | director | 16000 0.0129% | $66,880.00 | 0 | 1 | |
| MARTIN LOIS M | director | 1000 0.0008% | $4,180.00 | 1 | 0 | |
| Rehfeld John E | director | 1000 0.0008% | $4,180.00 | 1 | 0 |
$3,611,891 | 113 | 13.40% | $568.07M | |
$860,541,348 | 82 | -5.10% | $522.02M | |
$63,049,419 | 31 | 2.87% | $591.5M | |
$112,238,340 | 19 | 39.16% | $482.32M | |
$2,516,932 | 19 | -15.78% | $471.34M | |
$3,556,951 | 18 | 9.64% | $497.63M | |
$46,858,891 | 18 | -11.58% | $576.47M | |
$8,069,667 | 13 | -13.57% | $506.32M | |
$57,263,116 | 11 | -8.37% | $485.42M | |
$19,167,169 | 10 | 28.48% | $576.83M | |
$75,069,528 | 10 | 19.77% | $568.45M | |
$49,165,200 | 7 | 12.92% | $599.48M | |
$94,000,000 | 7 | -20.84% | $597.49M | |
$88,549,962 | 5 | -16.91% | $483.55M | |
$1,746,565 | 4 | -29.05% | $510.69M | |
$144,224 | 4 | 21.31% | $483.6M | |
$58,352 | 4 | -43.78% | $495.18M | |
ADC Therapeutics SA (ADCT) | $2,857,000 | 2 | -5.23% | $517.81M |
$300,016 | 1 | -50.33% | $539.17M |
| Increased Positions | 67 | +76.14% | 17M | +24.81% |
| Decreased Positions | 33 | -37.5% | 5M | -8.23% |
| New Positions | 27 | New | 8M | New |
| Sold Out Positions | 12 | Sold Out | 1M | Sold Out |
| Total Postitions | 122 | +38.64% | 78M | +16.58% |
| Redmile Group, Llc | $55,147.00 | 12.63% | 15.67M | 0 | 0% | 2025-09-30 |
| Point72 Asset Management, L.P. | $28,637.00 | 6.56% | 8.14M | +371,993 | +4.79% | 2025-09-30 |
| Prosight Management, Lp | $26,303.00 | 6.03% | 7.47M | -3M | -28.62% | 2025-09-30 |
| Orbimed Advisors Llc | $20,794.00 | 4.76% | 5.91M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $15,881.00 | 3.64% | 4.51M | -9,644 | -0.21% | 2025-09-30 |
| Morgan Stanley | $12,915.00 | 2.96% | 3.67M | +623,494 | +20.47% | 2025-09-30 |
| Nantahala Capital Management, Llc | $7,977.00 | 1.83% | 2.27M | 0 | 0% | 2025-09-30 |
| Goldman Sachs Group Inc | $5,612.00 | 1.29% | 1.59M | +51,832 | +3.36% | 2025-09-30 |
| Tcg Crossover Management, Llc | $4,893.00 | 1.12% | 1.39M | +1M | New | 2025-09-30 |
| Bank Of America Corp /De/ | $4,792.00 | 1.1% | 1.36M | -837,769 | -38.1% | 2025-09-30 |